Lisinopril dose-response relationship in essential hypertension
- PMID: 2556172
- PMCID: PMC1379991
- DOI: 10.1111/j.1365-2125.1989.tb03521.x
Lisinopril dose-response relationship in essential hypertension
Abstract
1. This was a multicentre, double-blind, parallel study in 216 patients with mild to moderate (supine diastolic blood pressure = 95-115 mm Hg) essential hypertension. 2. After a 4-week placebo washout, patients were randomized to placebo or lisinopril 1.25, 5.20 or 80 mg once daily for 6 consecutive weeks. Supine and erect blood pressure was measured 24 h postdose at the end of weeks -2, 0, 2, 4, and 6. 3. There was a linear dose-response relationship for both supine and erect blood pressure. Diastolic blood pressure reductions in the lisinopril 20 and 80 mg day-1 groups were significantly greater than in the placebo or lisinopril 1.25 and 5 mg day-1 groups. 4. Lisinopril, at doses up to 80 mg day-1, was well tolerated.
Similar articles
-
Lisinopril: dose-peak effect relationship in essential hypertension.Br J Clin Pharmacol. 1988 May;25(5):533-8. doi: 10.1111/j.1365-2125.1988.tb03342.x. Br J Clin Pharmacol. 1988. PMID: 2841960 Free PMC article. Clinical Trial.
-
Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension.J Hum Hypertens. 1992 Aug;6(4):325-31. J Hum Hypertens. 1992. PMID: 1331444 Clinical Trial.
-
Enalapril and lisinopril in the treatment of mild to moderate essential hypertension.Clin Ther. 1990 Mar-Apr;12(2):181-90. Clin Ther. 1990. PMID: 2162258 Clinical Trial.
-
Telmisartan: a review of its use in hypertension.Drugs. 2001;61(10):1501-29. doi: 10.2165/00003495-200161100-00009. Drugs. 2001. PMID: 11558835 Review.
-
Lisinopril, a new angiotensin converting enzyme inhibitor.Am J Med Sci. 1992 May;303(5):340-4. doi: 10.1097/00000441-199205000-00015. Am J Med Sci. 1992. PMID: 1316080 Review. No abstract available.
Cited by
-
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.Clin Pharmacokinet. 2002;41(3):207-24. doi: 10.2165/00003088-200241030-00005. Clin Pharmacokinet. 2002. PMID: 11929321 Review.
-
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.Clin Pharmacokinet. 2013 Sep;52(9):793-803. doi: 10.1007/s40262-013-0073-6. Clin Pharmacokinet. 2013. PMID: 23696281 Clinical Trial.
-
Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.Hypertension. 2020 Apr;75(4):956-965. doi: 10.1161/HYPERTENSIONAHA.119.14504. Epub 2020 Feb 17. Hypertension. 2020. PMID: 32063059 Free PMC article. Clinical Trial.
-
Once-Daily Low Inflammatory Foods Everyday (LIFE) Smoothie or the Full LIFE Diet Lowers C-Reactive Protein and Raises Plasma Beta-Carotene in 7 Days.Am J Lifestyle Med. 2020 Oct 5;16(6):753-764. doi: 10.1177/1559827620962458. eCollection 2022 Nov-Dec. Am J Lifestyle Med. 2020. PMID: 36389047 Free PMC article.
-
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.Eur J Clin Pharmacol. 2006 Dec;62(12):989-93. doi: 10.1007/s00228-006-0218-8. Epub 2006 Nov 7. Eur J Clin Pharmacol. 2006. PMID: 17089106
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical